HomeREGULATORY
REGULATORY

Any CEA-Based Price Adjustment Must Be Limited to Premium Rates: 3 Pharma Groups
(Oct.11.2017)

Chuikyo 3-Way Subcommittee Meeting Holds Industry Hearing on Oct. 11
Major pharma trade groups of Japan, the US, and Europe stressed on October 11 that if a cost-effective assessment (CEA) system is to be introduced in Japan, any price adjustment as a result of such assessment should be limited to the correction premium portion of NHI prices, which are granted in initial drug pricing ...
(LOG IN FOR FULL STORY)

News Calendar